Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic myeloid leukemia (CML) treatment relies on tyrosine kinase inhibitors (TKIs).
• BCR-ABL1 kinase domain (KD) mutations are a primary cause of TKI resistance in CML.
• The T315I mutation presents a significant therapeutic challenge due to its resistance profile.

Purpose of the Study:

• To review the prevalence and impact of BCR-ABL1 KD mutations in CML patients treated with TKIs.
• To discuss the prognostic implications of these mutations.
• To provide an overview of current treatment guidelines and future mutation detection trends.

Main Methods:

• Literature review of studies on BCR-ABL1 KD mutations in CML.
• Analysis of mutation prevalence, resistance patterns, and clinical outcomes.
• Synthesis of information on treatment guidelines and diagnostic advancements.

Main Results:

• Numerous BCR-ABL1 KD mutations confer TKI resistance, with T315I being notably difficult to overcome.
• These mutations significantly affect patient prognosis and treatment efficacy.
• Understanding mutation profiles is crucial for personalized CML management.

Conclusions:

• BCR-ABL1 KD mutations are critical determinants of TKI response in CML.
• Targeted mutation detection and tailored treatment strategies are essential for improving patient outcomes.
• Ongoing research focuses on overcoming resistance, including novel therapies for mutations like T315I.